Subscribe: Biotechnology
http://rss.prnewswire.com/industry/bio
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced today  announced  calif march  company  march prnewswire  march  market  new  prnewswire  research  today announced  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Biotechnology

PR Newswire: Biotechnology



Press Releases from PR Newswire about Biotechnology



Published: Wed, 29 Mar 2017 09:20:59 EDT

Last Build Date: Wed, 29 Mar 2017 09:17:00 EDT

 



GeneNews Launches Blood-Based, Biomarker Test for Breast Cancer Risk Assessment

Wed, 29 Mar 2017 09:17:00 EDT

(image) Women with Elevated Risk Scores are Encouraged to Move to Further Screening with 3D Tomography, Screening Breast Ultrasound and/or MRI TORONTO, March 29, 2017 /PRNewswire/ - GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") announced today the launch of BreastSentry™, a new...



Media Files:
http://www.genenews.com/




University of Missouri Research Reactor Files for NRC Approval to Start U.S. Production of Medical Isotopes

Wed, 29 Mar 2017 09:00:00 EDT

(image) COLUMBIA, MO, March 29, 2017 /PRNewswire/ - The University of Missouri Research Reactor (MURR®) and its partners Nordion, a business of Sterigenics International, and General Atomics (GA), announce that MURR's License Amendment Request (LAR) has been submitted to the U.S. Nuclear...



Media Files:
http://www.nordion.com/




ViaCyte and W. L. Gore & Associates Announce Collaborative Research Agreement to Develop Novel Implantable Delivery Technologies for Cell Therapies

Wed, 29 Mar 2017 09:00:00 EDT

(image) SAN DIEGO and NEWARK, Del., March 29, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, and W. L. Gore & Associates, Inc. ("Gore"), a global materials science company, today announced a collaborative research agreement whereby the two companies will...



Media Files:
https://mma.prnewswire.com/media/483695/ViaCyte_and_Gore.jpg




Global Agricultural Chelates Market Analysis & Trends 2013-2016 & 2025 - Rapid Mordernization Impact on Agriculture in Emerging Economies - Research and Markets

Wed, 29 Mar 2017 08:30:00 EDT

(image) DUBLIN, Mar 29, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Agricultural Chelates Market Analysis & Trends - Industry Forecast to 2025" report to their offering. The Global Agricultural Chelates Market is poised to grow at a CAGR of...



Media Files:
http://photos.prnewswire.com/prnvar/20160330/349511LOGO




Global Medical Device Manufacturer Will Present a Case Study at the IVT Validation Week Europe Conference on the Efficient Paperless Validation Approach Through ValGenesis VLMS

Wed, 29 Mar 2017 08:30:00 EDT

(image) FREEMONT, Calif., March 29, 2017 /PRNewswire/ -- ValGenesis, Inc., the world's leading provider of Validation Lifecycle Management System (VLMS) software solutions, today announced that a globally renowned Medical Device manufacturer will be presenting a case study about their experience...



Media Files:
https://mma.prnewswire.com/media/483671/VALGENESIS_Logo.jpg




Cellecta, Inc. Launches Driver-Map™ Human Genome-Wide Gene Expression Profiling Kit for 19,000 Human Genes

Wed, 29 Mar 2017 08:30:00 EDT

(image) MOUNTAIN VIEW, Calif., March 29, 2017 /PRNewswire/ -- Cellecta, Inc. today announced the launch of the Driver-Map™ Human Genome-Wide Gene Expression Profiling kit, a targeted RNA expression profiling assay designed to easily provide a molecular snapshot of all known 19,000 human...



Media Files:
https://mma.prnewswire.com/media/483663/Driver_Map_kit_Cellecta_Inc.jpg




SHYFT Announces Strategic Investment From Optum

Wed, 29 Mar 2017 08:07:00 EDT

(image) WALTHAM, Mass., March 29, 2017 /PRNewswire/ -- SHYFT Analytics, the leading analytics cloud for life sciences, today announced it has secured a $7.5 million investment from Optum Ventures, closing out a strategically-lead $20 million Series B Round of funding that included McKesson and...



Media Files:
https://mma.prnewswire.com/media/483427/SHYFT_Analytics_Logo.jpg




Vermillion Announces Publication of Ovarian Cancer Symptoms Index Study

Wed, 29 Mar 2017 08:00:00 EDT

(image) AUSTIN, Texas, March 29, 2017 /PRNewswire/ -- Vermillion (NASDAQ: VRML) announced today the acceptance for publication of the original research titled, "Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy," by Renata R. Urban, MD,...



Media Files:
https://mma.prnewswire.com/media/483425/Vermillion_Logo.jpg




BioDigital Collaborates with Johns Hopkins Medicine to Power Ultimate Digital 3D Human Musculoskeletal Resource

Wed, 29 Mar 2017 08:00:00 EDT

(image) NEW YORK, March 29, 2017 /PRNewswire/ -- BioDigital, Inc., creators of the BioDigital Human Platform, announced today the collaboration of their 3D body mapping technology with the medical education expertise of Johns Hopkins Medicine. The new app - Muscle Anatomy: A Johns Hopkins Medicine...



Media Files:
https://mma.prnewswire.com/media/483637/BioDigital_Inc___3D_Human_Musculoskeletal_Resource.jpg




ClearLight Diagnostics to Present Data on the Multiplex 3D Imaging of the Tumor Microenvironment in a Variety of Preclinical and Clinical Cancer Models

Wed, 29 Mar 2017 07:54:00 EDT

(image) SUNNYVALE, Calif., March 29, 2017 /PRNewswire/ -- ClearLight Diagnostics, LLC, a developer of an automated next generation tissue processing and 3D imaging platform, announced today that it will present data at the 2017 American Association for Cancer Research meeting in Washington DC....



Media Files:
http://www.clearlightdx.com




Sangamo Therapeutics Announces Presentation of New Data Demonstrating Significant Reduction of Tau Expression Using Proprietary ZFP Gene Regulation Technology

Wed, 29 Mar 2017 07:30:00 EDT

(image) RICHMOND, Calif., March 29, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today the presentation of new human in vitro and animal model data demonstrating significant reduction of tau mRNA and tau protein expression...



Media Files:
https://mma.prnewswire.com/media/168403/sangamo_biosciences__inc__logo.jpg




Intec Pharma Provides Update on Phase III ACCORDANCE Study of the Accordion Pill Carbidopa/Levodopa in Parkinson's Disease Patients

Wed, 29 Mar 2017 07:30:00 EDT

JERUSALEM, March 29, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today provided an update on the ACCORDANCE study, the Company's global...



BioDuro launches humanized tumor microenvironment, three-dimensional drug screening and patient-derived xenograft verification platform: hTME-3DX Screen and Verify™

Wed, 29 Mar 2017 07:00:00 EDT

(image) SAN DIEGO, March 29, 2017 /PRNewswire/ -- BioDuro LLC, announced today the launch of hTME-3DX Screen and Verify, the first drug screening platform to combine humanized 3D cell culture and patient derived xenograft models, across a set of 300 proprietary tumor models.  The primary tumor ban...



Media Files:
http://photos.prnewswire.com/prnvar/20160106/319984LOGO




Biotech Stocks Under Scanner -- Celsion, Achillion Pharma, Tenax Therapeutics, and Cerulean Pharma

Wed, 29 Mar 2017 06:05:00 EDT

NEW YORK, March 29, 2017 /PRNewswire/ -- Stock-Callers.com redirects investors' attention to the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry also includes the manufacturing and marketing of drugs as a...



Egalet Announces U.S. Food and Drug Administration Does Not Object to Egalet's Distribution of Materials and Communications to Healthcare Professionals Regarding Abuse-Deterrent Properties of ARYMO™ ER via Intranasal Route

Wed, 29 Mar 2017 06:02:00 EDT

(image) WAYNE, Pa., March 29, 2017 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the U.S. Food and Drug...



Media Files:
https://mma.prnewswire.com/media/55007/egalet_corporation_logo.jpg




Biologics Market Size Worth $399.5 Billion By 2025 | Growth Rate: 3.9%: Grand View Research, Inc.

Wed, 29 Mar 2017 06:00:00 EDT

(image) SAN FRANCISCO, March 29, 2017 /PRNewswire/ -- The global biologics market is anticipated to reach USD 399.5 billion by 2025, according to a new report by Grand View Research, Inc. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine a...



Media Files:
http://photos.prnewswire.com/prn/20150105/723757




ARMO BioSciences Announces First Patient Dosed in Pivotal Phase 3 Trial of Immunotherapy AM0010 for Advanced Pancreatic Cancer

Wed, 29 Mar 2017 06:00:00 EDT

(image) REDWOOD CITY, Calif., March 29, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a clinical-stage immuno-oncology company, announced that the first patient has been dosed in the Company's international Phase 3 pivotal clinical trial to evaluate its lead investigational immuno-oncology drug...



Media Files:
http://www.armobio.com




Downstream Processing Market Worth 22.03 Billion USD by 2021

Wed, 29 Mar 2017 05:30:00 EDT

(image) PUNE, India, March 29, 2017 /PRNewswire/ -- According to a new market research report "Downstream Processing Market by Technique (Separation, Concentration, Purification), Product (Chromatography Column & Resin, Filter, Single use), Application (Mab Production), End User (Contract...



Media Files:
http://photos.prnewswire.com/prn/20160303/792302




Positive Results of Phase 2b Clinical Trial of Pharmalink's Nefecon in Primary IgA Nephropathy Published in The Lancet

Wed, 29 Mar 2017 04:00:00 EDT

STOCKHOLM, March 29, 2017 /PRNewswire/ -- Pharmalink AB, a specialty pharma company, announces that positive results and analyses from the completed Phase 2b trial of its oral drug candidate Nefecon® in primary IgA nephropathy (IgAN) patients have been published online in The Lancet...



JHL Doses First Patient In JHL1101 Phase I European Trial

Wed, 29 Mar 2017 03:05:00 EDT

(image) HSINCHU, Taiwan and WUHAN, China, March 29, 2017 /PRNewswire/ -- JHL Biotech Inc. (Stock Code: 6540.TWO) today announced that the first patient has been dosed in the company's Phase I clinical trial of JHL1101 (a proposed rituximab biosimilar) in rheumatoid arthritis patients. The...



Media Files:
https://mma.prnewswire.com/media/333015/jhl_Logo.jpg